USFDA issued EIR to Torrent Pharma: Gujarat

1321
USFDA Inspection audit
USFDA Inspection

Last Updated on December 31, 2023 by The Health Master

USFDA issued EIR

Torrent Pharmaceuticals, a leading pharmaceutical company, announced that the USFDA issued EIR.

The United States Food and Drug Administration (USFDA) has issued an encouraging Establishment Inspection Report (EIR) for the company’s manufacturing facility located in Dahej, Gujarat.

This development signifies a significant step towards improved operations and growth prospects for Torrent Pharmaceuticals.

Successful Closure of the Inspection:

Following the issuance of the EIR by the USFDA, Torrent Pharmaceuticals confirmed the successful closure of the inspection.

This achievement underscores the company’s commitment to maintaining high manufacturing standards and regulatory compliance.

The closure of the inspection holds substantial implications for Torrent Pharmaceuticals’ future endeavors.

Progress from the Previous Setback:

In a notable turnaround, the Dahej facility faced regulatory challenges in March 2019 when it was placed under Official Action Indicated (OAI) status by the USFDA.

However, Torrent Pharmaceuticals diligently addressed the concerns and worked towards rectifying the issues.

Re-inspection and Observations:

The USFDA conducted a re-inspection of the Dahej facility in May of the current year, spanning from May 17 to May 25.

Following this re-inspection, the regulatory body issued a Form 483 outlining two observations related to the facility’s operations.

As part of their dedication to quality and compliance, the company took meticulous steps to address these observations.

Upgraded Site Classification:

As a positive outcome of the re-inspection process and subsequent efforts, the site’s classification has been upgraded to Voluntary Action Indicated (VAI).

This upgraded status is indicative of the strides made by Torrent Pharmaceuticals in resolving the previously highlighted concerns.

The new classification holds promising implications for the company’s future endeavors in the United States pharmaceutical market.

Impetus for Growth and Product Offerings:

The improved classification of the Dahej facility augments Torrent Pharmaceuticals’ growth prospects in the highly competitive US pharmaceutical market.

This positive development opens doors for the company to introduce new and innovative product offerings, thereby expanding its market presence and catering to diverse healthcare needs.

Manufacturing Spectrum:

The Dahej facility specializes in the production of Active Pharmaceutical Ingredients (APIs) and formulations, catering to Torrent Pharma’s international markets.

The facility’s global reach underscores its significance as a key contributor to the company’s operations and growth trajectory.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news